Cargando…

Major milestones in translational oncology

Translational oncology represents a bridge between basic research and clinical practice in cancer medicine. Today, translational research in oncology benefits from an abundance of knowledge resulting from genome-scale studies regarding the molecular pathways involved in tumorigenesis. In this Forum...

Descripción completa

Detalles Bibliográficos
Autores principales: Dragani, Tommaso A., Castells, Antoni, Kulasingam, Vathany, Diamandis, Eleftherios P., Earl, Helena, Iams, Wade T., Lovly, Christine M., Sedelaar, J. P. Michiel, Schalken, Jack A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964079/
https://www.ncbi.nlm.nih.gov/pubmed/27469586
http://dx.doi.org/10.1186/s12916-016-0654-y
_version_ 1782445041784979456
author Dragani, Tommaso A.
Castells, Antoni
Kulasingam, Vathany
Diamandis, Eleftherios P.
Earl, Helena
Iams, Wade T.
Lovly, Christine M.
Sedelaar, J. P. Michiel
Schalken, Jack A.
author_facet Dragani, Tommaso A.
Castells, Antoni
Kulasingam, Vathany
Diamandis, Eleftherios P.
Earl, Helena
Iams, Wade T.
Lovly, Christine M.
Sedelaar, J. P. Michiel
Schalken, Jack A.
author_sort Dragani, Tommaso A.
collection PubMed
description Translational oncology represents a bridge between basic research and clinical practice in cancer medicine. Today, translational research in oncology benefits from an abundance of knowledge resulting from genome-scale studies regarding the molecular pathways involved in tumorigenesis. In this Forum article, we highlight the state of the art of translational oncology in five major cancer types. We illustrate the use of molecular profiling to subtype colorectal cancer for both diagnosis and treatment, and summarize the results of a nationwide screening program for ovarian cancer based on detection of a tumor biomarker in serum. Additionally, we discuss how circulating tumor DNA can be assayed to safely monitor breast cancer over the course of treatment, and report on how therapy with immune checkpoint inhibitors is proving effective in advanced lung cancer. Finally, we summarize efforts to use molecular profiling of prostate cancer biopsy specimens to support treatment decisions. Despite encouraging early successes, we cannot disregard the complex genetics of individual susceptibility to cancer nor the enormous complexity of the somatic changes observed in tumors, which urge particular attention to the development of personalized therapies.
format Online
Article
Text
id pubmed-4964079
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49640792016-07-29 Major milestones in translational oncology Dragani, Tommaso A. Castells, Antoni Kulasingam, Vathany Diamandis, Eleftherios P. Earl, Helena Iams, Wade T. Lovly, Christine M. Sedelaar, J. P. Michiel Schalken, Jack A. BMC Med Forum Translational oncology represents a bridge between basic research and clinical practice in cancer medicine. Today, translational research in oncology benefits from an abundance of knowledge resulting from genome-scale studies regarding the molecular pathways involved in tumorigenesis. In this Forum article, we highlight the state of the art of translational oncology in five major cancer types. We illustrate the use of molecular profiling to subtype colorectal cancer for both diagnosis and treatment, and summarize the results of a nationwide screening program for ovarian cancer based on detection of a tumor biomarker in serum. Additionally, we discuss how circulating tumor DNA can be assayed to safely monitor breast cancer over the course of treatment, and report on how therapy with immune checkpoint inhibitors is proving effective in advanced lung cancer. Finally, we summarize efforts to use molecular profiling of prostate cancer biopsy specimens to support treatment decisions. Despite encouraging early successes, we cannot disregard the complex genetics of individual susceptibility to cancer nor the enormous complexity of the somatic changes observed in tumors, which urge particular attention to the development of personalized therapies. BioMed Central 2016-07-28 /pmc/articles/PMC4964079/ /pubmed/27469586 http://dx.doi.org/10.1186/s12916-016-0654-y Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Forum
Dragani, Tommaso A.
Castells, Antoni
Kulasingam, Vathany
Diamandis, Eleftherios P.
Earl, Helena
Iams, Wade T.
Lovly, Christine M.
Sedelaar, J. P. Michiel
Schalken, Jack A.
Major milestones in translational oncology
title Major milestones in translational oncology
title_full Major milestones in translational oncology
title_fullStr Major milestones in translational oncology
title_full_unstemmed Major milestones in translational oncology
title_short Major milestones in translational oncology
title_sort major milestones in translational oncology
topic Forum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964079/
https://www.ncbi.nlm.nih.gov/pubmed/27469586
http://dx.doi.org/10.1186/s12916-016-0654-y
work_keys_str_mv AT draganitommasoa majormilestonesintranslationaloncology
AT castellsantoni majormilestonesintranslationaloncology
AT kulasingamvathany majormilestonesintranslationaloncology
AT diamandiseleftheriosp majormilestonesintranslationaloncology
AT earlhelena majormilestonesintranslationaloncology
AT iamswadet majormilestonesintranslationaloncology
AT lovlychristinem majormilestonesintranslationaloncology
AT sedelaarjpmichiel majormilestonesintranslationaloncology
AT schalkenjacka majormilestonesintranslationaloncology